Verastem amends Oberland note agreement, adds new revenue-linked notes tranche
The amendment creates a $75 million Revenue Notes series tied to product sales, replacing prior conditional tranches of Initial Notes.
SEC filing
Latest
5 stories
Thursday, September 17
Thursday, August 6
Verastem starts dosing in all three VS-7375 registration trials, secures added $75M financing
The company reported Q2 2026 results alongside new KRAS G12D trial progress and a royalty deal with Oberland Capital that extends its projected cash runway.
SEC filing